Masitinib Emerges as Potential Game-Changer in MS Treatment

AB Science SA has announced that The Life Sciences Magazine has featured an article on masitinib and its phase 3 principal investigator, the neurologist, Professor Patrick Vermersch. Renowned in neurology, Vermersch is pioneering research into masitinib as a therapeutic option for progressive multiple sclerosis (MS). His research emphasizes the role of neuroinflammation in neurodegenerative disorders like MS, Alzheimer's, and Parkinson's disease.

Masitinib targets mast cells and microglia, key players in neuroinflammation, offering potentially groundbreaking treatment for progressive MS, where current options are limited. Promising results from Phase IIB/III trials show masitinib's potential in reducing neuroinflammation and slowing disease progression.

This innovative approach positions AB Science's compound as a hopeful solution for MS patients, with upcoming Phase III data anticipated to further identify suitable patient groups.